Investigator-Initiated Study Shows Switching to Afrezza® Improves Glucose Control with No Additional Hypoglycemia in T2DM

Written by Customer Service on June 13, 2020. Posted in Public Companies.

WESTLAKE VILLAGE, Calif., June 13, 2020 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza® (insulin human) Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sessions during the ePoster session (Poster 990) on Saturday, June 13, 2020.The lead author, Mark Kipnes, MD (Diabetes and Glandular Disease Clinic, San Antonio, Texas) presented clinical data from an investigator-initiated observational “switch” study that evaluated quality of life and glucose control in patients with type 2 diabetes previously treated with injected mealtime insulin. Following conversion to Afrezza, patients were followed for 14 weeks, and glucose control (measured by both A1C and glucose time in range), rates of hypoglycemia and quality of life were assessed.Study...

Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions

Written by Customer Service on June 13, 2020. Posted in Public Companies.

THE WOODLANDS, Texas, June 13, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today presented six posters for ZynquistaTM (sotagliflozin) at the virtual 80th American Diabetes Association (ADA) Scientific Sessions including additional efficacy and safety data patients with type 2 diabetes and moderate and severe renal impairment.Phase 3 CKD-3 StudyIn the Phase 3, multicenter, randomized, double-blind, placebo-controlled CKD-3 study, sotagliflozin was tested for superiority versus placebo in reducing A1C after 26 weeks of treatment in patients with type 2 diabetes, inadequate glycemic control and moderate (CKD Stage 3) renal impairment.The study met its primary endpoint, demonstrating that sotagliflozin 400 mg significantly reduced A1C in the entire population of patients with moderate renal impairment compared...

Switching to Ozempic® from another GLP-1 RA significantly reduced blood sugar and weight in people with type 2 diabetes in routine clinical practice

Written by Customer Service on June 13, 2020. Posted in Public Companies.

· A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) were significantly more likely to reach their blood sugar goals and lose weight compared to adding a further oral antidiabetic drug(s) or insulin.1Bagsværd, Denmark, 13 June 2020 – Novo Nordisk today announced results from two real-world studies: EXPERT, which confirms the efficacy Ozempic® (once‑weekly semaglutide) demonstrated in the SUSTAIN clinical trial programme, and PATHWAY, which supports recommendations in clinical guidelines by showing that initiation of a GLP-1 receptor agonist (GLP-1 RA) helps people with type 2 diabetes reach their blood sugar goals (measured by HbA1c) while also losing weight. These studies, which analysed data from US databases,...

Medtronic Shares Study Results on First of Its Kind Extended Wear Infusion Set from American Diabetes Association Conference

Written by Customer Service on June 13, 2020. Posted in Public Companies.

DUBLIN, June 13, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced data on its extended wear infusion set presented at the virtual 80th Scientific Sessions of the American Diabetes Association (ADA). Infusion sets allow people on insulin pump therapy to deliver insulin under the skin to maintain healthy blood glucose levels. Current generation infusion sets must be changed every two to three days. The research revealed that Medtronic Extended infusion sets last twice as long as standard infusion sets with study results suggesting they could provide safe and comfortable wear for patients using Medtronic insulin pumps. It is the only infusion set in the industry with the ability to be used for up to 7 days and adds to the portfolio of technology offerings from Medtronic which...

vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients

Written by Customer Service on June 13, 2020. Posted in Public Companies.

– Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or diabetic ketoacidosis (DKA) –HIGH POINT, N.C., June 13, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) today made two presentations at the American Diabetes Association’s 80th Scientific Sessions. The clinical data presented from the positive Phase 2 Simplici-T1 Study confirms the potential for TTP399 to provide a benefit beyond standalone insulin treatment for patients living with type 1 diabetes.“These results from the Simplici-T1 Trial are a major step towards the future of care in type 1 diabetes. They demonstrate that TTP399, a once-a-day pill, reduces HbA1c and improves time in range, without increasing hypoglycemia or any signal for adverse events including...

Zealand Pharma presents elaborated results on the use of regular human insulin delivered by V-Go® in older adults with type 2 diabetes, at the 80th Scientific Sessions of the American Diabetes Association

Written by Customer Service on June 13, 2020. Posted in Public Companies.

Press release – No. 08 / 2020Zealand Pharma presents elaborated results on the use of regular human insulin delivered by V-Go® in older adults with type 2 diabetes, at the 80th Scientific Sessions of the American Diabetes Association

The Annual General Meeting and Extraordinary General Meeting of shareholders of ArcelorMittal (“General Meetings”) held today approved all resolutions by a strong majority.

Written by Customer Service on June 13, 2020. Posted in Public Companies.

The Annual General Meeting and Extraordinary General Meeting of shareholders of ArcelorMittal (“General Meetings”) held today approved all resolutions by a strong majority.Luxembourg 13 June 2020 (13:00 CET) – 68% of the voting rights were represented at the General Meetings. In view of the Covid-19 outbreak, the Board of Directors of ArcelorMittal (the “Company”) had decided to hold this year’s General Meetings by virtual-only format, as permitted by Luxembourg law. Arrangements were made to allow shareholders to vote electronically and by proxy voting. The results of the votes will be posted shortly on www.arcelormittal.com under “Investors – Equity investors – Shareholders-events – AGM – Annual General Meeting and Extraordinary General Meeting of shareholders, 13 June 2020” where the full documentation regarding the General...

Production report for May 2020

Written by Customer Service on June 13, 2020. Posted in Public Companies.

13 June 2020Below please find average gross operated production in May 2020 and corresponding numbers for April 2020.Barrels of oil equivalents per dayBarrels of oil per dayAs of Ma 5th, Puli C fields have been slowly and steady being re-opened on a well by well basisOperated by Selva Maria Oil on behalf of IOX until local authorities approves operator’s licence.***************************Interoil Exploration and Production ASA is a Norwegian based exploration and production company – listed on the Oslo Stock Exchange – with focus on Latin America. The Company is operator and license holder of several production and exploration assets in Colombia and Argentina. Interoil currently employs approximately 50 people and is headquartered in Oslo.This information is subject to the disclosure requirements pursuant to section...

Zosano Pharma to showcase new post-hoc analyses of Qtrypta’s (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 American Headache Society’s Virtual Annual Scientific Meeting Platform

Written by Customer Service on June 13, 2020. Posted in Public Companies.

FREMONT, Calif., June 13, 2020 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that new post-hoc efficacy analyses of QtryptaTM, Zosano’s lead investigational product candidate for the acute treatment of migraine, will be presented as a virtual oral presentation on the 2020 American Headache Society’s Virtual Annual Scientific Meeting Platform.Six different measurements of pain reduction from the exploratory efficacy results in the long-term safety study (“LTSS”) were examined and compared to the positive clinical results observed in the Phase 2/3 Zotrip study. Across all six efficacy measurements, which included pain freedom and pain relief at 2 hours, clinical activity observed in the LTSS during the one-year trial period treating approximately 6,000 attacks...

Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020

Written by Customer Service on June 13, 2020. Posted in Public Companies.

Phase III VIALE-A study showed Venclexta/Venclyxto plus azacitidine helped people with the most common type of aggressive adult leukaemia live longer compared to azacitidine aloneData will be presented as a late-breaking abstract at the 25th European Hematology Association Virtual CongressBasel, 13 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the phase III VIALE-A study, evaluating Venclexta®/Venclyxto® (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy. VIALE-A results were featured in the 25th European Hematology Association Virtual Congress Press Briefing on Saturday 13 June 2020 at 08:30 CEST and will be presented at the congress during the Late-breaking Oral Session (abstract...

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Day: June 13, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice